What is PCSA's current stock price?

PCSA (Processa Pharmaceuticals, Inc.) is currently trading at $2.51 with a market cap of $5.7M.

What sector is Processa Pharmaceuticals, Inc. in?

Processa Pharmaceuticals, Inc. (PCSA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PCSA a good stock to buy?

Analysts have a Buy consensus on PCSA with a price target of $225.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PCSA Processa Pharmaceuticals, Inc.

Healthcare

$2.51+0.00%OpenMarket Cap: $5.7M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.74

P/S

0.00

EV/EBITDA

-0.30

DCF Value

$3.49

FCF Yield

-204.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-281.3%

ROA

-312.0%

ROIC

-569.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-3.4M	$—
Q4 null	$0.00	$-3.4M	$—
FY null	$0.00	$-13.6M	$—
Q3 null	$0.00	$-3.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$225.00

Target (Median)

$225.00

Target Range

$225.00 - $225.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2025-09-02

HC Wainwright & Co.Buy

2025-06-30

Trading Activity

Insider Trades

View All

Young Daviddirector, officer: Pres. Research & Development

BuyTue May 19

SKIBSTED RUSSELLofficer: Chief Financial Officer

BuyTue May 19

Ng George Kdirector, officer: Chief Executive Officer

BuyTue May 19

Lin Patrickofficer: Chief Business - Strategy Off

BuyTue May 19

Guy Wendyofficer: Chief Administrative Officer

BuyTue May 19

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.01

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

Peers